News for Genmab A/S (GMABN.MX)

**media[601470]**

**media[595355]**

**media[594437]**

**media[591891]**

**media[588774]**

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a look at whereGenmab A/S (NASDAQ:GMAB) stands against other most profitable biotech stocks to buy right now. With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining […]

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now.

We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against other most undervalued healthcare stocks to buy according to analysts. Rising Healthcare Costs and the Impact of Tariffs on US-China Trade in […]

**media[581736]**

Denmark-based Genmab A/S (GMAB) and U.S.-based BridgeBio Pharma (BBIO) have secured regulatory approval from Japan's Ministry of Health, Labour and Welfare for

**media[576563]**

**media[573399]**

[url="]Genmab A/S[/url] (Nasdaq: GMAB) announced today updated data from cohort B1 of the Phase 1/2 RAINFOL-01 study of rinatabart sesutecan (Rina-S®), an inv

Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an analysis of GMAB stock now.

**media[564804]**

**media[564802]**

**media[564623]**

Genmab A/S said that Johnson & Johnson has decided not to exercise its option to obtain a worldwide license for the development of HexaBody-CD38.

Genmab A/S (GMAB) Monday announced that Johnson & Johnson (JNJ) has decided not to exercise its option to develop and commercialize HexaBody-CD38 for multiple myeloma, for a worldwide license.